Table 3.
COVID-19 and CMV Treatment Characteristics
| All Patients (n = 80) | Treatment (n = 43) | Control (n = 37) | P Value | |
|---|---|---|---|---|
| Remdesivir | 52 (65) | 28 (65.1) | 24 (64.9) | .981 |
| Days of therapy, median (IQR) | 10 (5–10) | 10 (6–10) | 6 (5–10) | .066 |
| Tocilizumab | 36 (45.0) | 22 (51.2) | 14 (37.8) | .333 |
| Glucocorticoid use | 79 (99) | 43 (100) | 36 (97) | .462 |
| Dexamethasone | 58 | 33 (76.7) | 25 (67.6) | .506 |
| Methylprednisolone | 38 | 18 (41.9) | 20 (54.1) | .387 |
| Prednisone | 13 | 7 (16.3) | 6 (16.2) | .994 |
| Hydrocortisone | 39 | 21(48.8) | 18 (47.6) | .987 |
| Total dexamethasone dose equivalents, median (IQR), mg | 254 (160–432) | 309 (186–543) | 188 (138–313) | .017 |
| Ganciclovir duration, median (IQR), d (n = 40a) | – | 15 (8–27) | – | – |
| Time from CMV viremia to start of treatment, median (IQR), d (n = 40) | – | 3 (2–7) | – | – |
| Valganciclovir duration, median (IQR), d (n = 17a) | – | 11 (7–15) | – | – |
| Total duration CMV viremia treatment, median (IQR), d | – | 19 (9–30) | – | – |
| Infectious diseases consult | 62 (77.5) | 34 (79.1) | 28 (75.7) | .925 |
All values presented as No. (%) unless otherwise specified.
Abbreviations: CMV, cytomegalovirus; COVID-19, coronavirus disease 2019; IQR, interquartile range.
a
Three patients received valganciclovir only.